ArticleJournal of cancer research and clinical oncology2023

Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management.

Ruishan Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.